CytomX Therapeutics, Inc. (CTMX)

CytomX director Mani Mohindru received 59,000 stock options at a $2.96 exercise price, vesting by the earlier of first anniversary or 2027 meeting, expiring in 2036.

Director Elaine V. Jones receives 59,000 CytomX stock options at a $2.96 exercise price, vesting by the 2027 annual meeting if she continues board service.

Following the last earnings report on May 7, 2026, CytomX Therapeutics (CTMX)'s stock price moved — from — to —.

CTMX fell 8.41% as several oncology/biotech peers also traded lower: ADCT -5.51%, AUTL -3.04%, IMAB -1.49%, LRMR -4.9%, TECX -3.79%. With 5 peers moving in the same (down) direction, the weakness appears partly sector-driven despite the positive collaboration expansion. ... Recent news often aligns …

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss of 9 cents per share. Stock fell 3.9% on Friday.